CK0804, a regulatory T cell therapy, received FDA orphan drug designation for myelofibrosis, supporting rare disease treatment development. Clinical study results showed significant reductions in ...
Published on January 6, 2026, in Volume 2 of the Immunity & Inflammation journal, the review begins by underscoring Professor Taniguchi's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback